Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 19: 86-91, 1973;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seidel, D.
Right arrow Articles by Ruppert, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seidel, D.
Right arrow Articles by Ruppert, C.

Clinical Chemistry, Vol 19, 86-91, Copyright © 1973 by the American Association for Clinical Chemistry

Significance of the LP-X Test in Differential Diagnosis of Jaundice

D. Seidel 1, H. Gretz 1, and Claudia Ruppert 1

1 From the Medical Clinic (Ludolf-Krehl-Klinik) University of Heidelberg Medical School, Bergheimerstrasse 58, 69 Heidelberg, G.F.R.

In recent years it has been well documented that the characteristic increase in plasma lipoproteins in patients with obstructive jaundice is the result of the presence of a low-density lipoprotein (relative density 1.006-1.063 g/ml) of abnormal composition and properties. This abnormal lipoprotein has been designated "LP-X." The development of a simple immunologic test system for determining LP-X provides the basis for a new clinical chemical test that is of use in the differential diagnosis of jaundice. In this study, 2680 LP-X determinations were performed on 1481 subjects: 1309 patients with or without liver disease, and 172 healthy volunteers. Statistical analysis of this series revealed a power of 0.99 and a specifity of 0.98 to demonstrate or exclude cholestasis. In this regard the new test is superior to other blood-chemical assessments. It was never positive in patients without liver disease. However, the LP-X test alone is not adequate to distinguish between intrahepatic cholestasis and extrahepatic biliary obstruction


Key Words: Plasma lipoproteins • liver disease • immunochemical test to demonstrate or exclude cholestasis • diagnostic aid • alkaline phosphatase assay compared • normal values • serum aminotransferase (SGOT, SGPT) activities

Submitted on October 3, 1972
Accepted on November 9, 1972






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1973 by the American Association for Clinical Chemistry.